About
Acceptance rate:
9%
Time to first decision with review:
54 days*
Time from acceptance to publication:
24 days*
Impact Factor:
3.8
Impact Factor rank (JCR):
13/95
Citescore:
10.3
Aims and scope
British Journal of Ophthalmology is an international peer-reviewed journal for ophthalmologists and visual science specialists that publishes clinical investigations, clinical observations, and clinically relevant laboratory investigations related to ophthalmology. Main features include articles on both clinical and laboratory sciences, up-to-date major reviews, editorials, education articles and letters. The 'Innovations' section features papers on surgical, diagnostic and therapeutic innovations.
British Journal of Ophthalmology is BMJ's flagship ophthalmology journal and has an open access companion journal, BMJ Open Ophthalmology.
For information about the British Journal of Ophthalmology editorial team and the Editor-in-Chief, Frank Larkin, please refer to the Editorial Board page.
Plan S compliance
British Journal of Ophthalmology is a Plan S compliant Transformative Journal. Transformative Journals are one of the compliance routes offered by cOAlition S funders, such as Wellcome, WHO and UKRI. Find out more about Transformative Journals and Plan S compliance on our Author Hub.
Journal information
Ownership
British Journal of Ophthalmology is owned by BMJ
Publication Model
Subscription; with hybrid open access option
Frequency
Monthly
Launch date
1917
Indexed by
Web of Science Core Collection: Science Citation Index, Science Citation Index Expanded; BIOSIS Previews, Current Contents: Clinical Medicine, Life Sciences; MEDLINE (Index Medicus), PubMed Central (BMJ Open Access Special Collection), Scopus, Embase (Excerpta Medica), CINAHL, Google Scholar
Peer review model
Single anonymised; the names of reviewers are hidden from the author
Print ISSN
0007-1161
Online ISSN
1468-2079
Journal Statistics 2023
Acceptance rate: 9%
Speed
Time to first decision without review: 5 days (median)
Time to first decision with review: 54 days (median)
Time from acceptance to publication: 24 days (median)
Impact
Impact Factor category: Ophthalmology
Impact Factor (JCR): 3.8
Impact Factor rank: 14/95
5 Year Impact Factor: 3.9
Journal Citation Indicator: 1.94
Eigenfactor: 0.01924
Citescore: 10.3
Citescore rank: 6/137
Scimago Journal rank (SJR): 1.862
Reach
2023 total content views: 779,116
2023 total Altmetric mentions: 2,572
The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure.
How we get these metrics
Contact information
For all contact information please refer to the Contact Us page.
For authors
Please refer to the Instructions for Authors.
To advertise
Subscriptions
Rights and permissions
Affiliations
BJO is affiliated with The Bowman Club, founded in 1999, is the UK corneal specialty group. It facilitates collaborative research, represents the subspecialty to external parties and hosts an annual meeting featuring the Professor David Easty Annual Lecture. Invited international speakers is an important aspect to this meeting. UK ophthalmologists with subspecialty interest in cornea and external eye diseases attend the annual BOWMAN Club meeting where latest advances and clinical updates are discussed with an aim to promote best practice in the management of cornea and external eye disorders.
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported